Payment overview · 2025
General Payments
$1,263.64
69 reported records · 21 companies
Healthcare provider profile · identity verified
Stephen B Fortson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PELL CITY, AL · NPI 1073819058
Verified facts
What the public records show
CMS Open Payments records show Stephen B Fortson, MD received $1,263.64 in general payments during 2025 across 69 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 257 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 279 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulance by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $226.63 | 17.9% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $200.86 | 15.9% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $163.73 | 13.0% | 10 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $104.27 | 8.2% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $83.02 | 6.6% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $81.37 | 6.4% | 4 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $66.29 | 5.2% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $57.29 | 4.5% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $38.83 | 3.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.11 | 2.3% | 2 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $26.51 | 2.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $24.47 | 1.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $21.54 | 1.7% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $20.90 | 1.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.31 | 1.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.40 | 1.5% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $18.24 | 1.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.62 | 1.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.60 | 1.3% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.74 | 1.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.91 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,263.64 | 69 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $200.86 | 14 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $124.86 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $114.77 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $104.27 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $101.77 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $96.40 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $83.02 | 4 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $66.29 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $43.74 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $43.74 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $40.04 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $38.83 | 2 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $38.49 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.11 | 2 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $26.51 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $24.47 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $20.45 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.31 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.80 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 279 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 61 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 236 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 175 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
55 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
146 | 36 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
21 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
175 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
257 | 55 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
61 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
236 | 45 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
279 | 70 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 816 | 214 |
| Gabapentin | Gabapentin | 731 | 149 |
| Levothyroxine Sodium | Levothyroxine Sodium | 661 | 161 |
| Amlodipine Besylate | Amlodipine Besylate | 610 | 172 |
| Carvedilol | Carvedilol | 555 | 153 |
| Pantoprazole Sodium | Pantoprazole Sodium | 513 | 153 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 452 | 144 |
| Metformin Hcl Er | Metformin Hcl | 411 | 122 |
| Pregabalin | Pregabalin | 405 | 76 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 402 | 75 |
| Celecoxib | Celecoxib | 394 | 131 |
| Furosemide | Furosemide | 393 | 119 |
| Lisinopril | Lisinopril | 372 | 102 |
| Omeprazole | Omeprazole | 339 | 110 |
| Tizanidine Hcl | Tizanidine Hcl | 339 | 99 |
| Trazodone Hcl | Trazodone Hcl | 319 | 93 |
| Valsartan | Valsartan | 312 | 87 |
| Losartan Potassium | Losartan Potassium | 311 | 102 |
| Tamsulosin Hcl | Tamsulosin Hcl | 308 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 283 | 74 |
| Eliquis | Apixaban | 279 | 70 |
| Montelukast Sodium | Montelukast Sodium | 275 | 86 |
| Tramadol Hcl | Tramadol Hcl | 258 | 72 |
| Jardiance | Empagliflozin | 257 | 55 |
| Mirtazapine | Mirtazapine | 249 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 236 | 75 |
| Ozempic | Semaglutide | 236 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 235 | 73 |
| Fluticasone Propionate | Fluticasone Propionate | 228 | 86 |
| Buspirone Hcl | Buspirone Hcl | 210 | 53 |
| Famotidine | Famotidine | 207 | 49 |
| Potassium Chloride | Potassium Chloride | 205 | 62 |
| Clonazepam | Clonazepam | 200 | 30 |
| Ipratropium Bromide | Ipratropium Bromide | 190 | 89 |
| Prednisone | Prednisone | 188 | 127 |
| Duloxetine Hcl | Duloxetine Hcl | 186 | 45 |
| Lorazepam | Lorazepam | 180 | 44 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 175 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 171 | 64 |
| Xarelto | Rivaroxaban | 150 | 22 |
| Farxiga | Dapagliflozin Propanediol | 146 | 36 |
| Glipizide Er | Glipizide | 140 | 38 |
| Alendronate Sodium | Alendronate Sodium | 134 | 42 |
| Atenolol | Atenolol | 130 | 38 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 130 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 127 | 34 |
| Metformin Hcl | Metformin Hcl | 122 | 31 |
| Telmisartan | Telmisartan | 117 | 35 |
| Bupropion Xl | Bupropion Hcl | 115 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 113 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 112 | 34 |
| Donepezil Hcl | Donepezil Hcl | 111 | 28 |
| Spironolactone | Spironolactone | 108 | 32 |
| Memantine Hcl | Memantine Hcl | 106 | 32 |
| Oxybutynin Chloride | Oxybutynin Chloride | 106 | 33 |
| Dapagliflozin | Dapagliflozin Propanediol | 105 | 17 |
| Divalproex Sodium | Divalproex Sodium | 102 | 25 |
| Sertraline Hcl | Sertraline Hcl | 101 | 31 |
| Baclofen | Baclofen | 99 | 42 |
| Aripiprazole | Aripiprazole | 96 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 95 | 30 |
| Alprazolam | Alprazolam | 93 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 93 | 24 |
| Levetiracetam | Levetiracetam | 84 | 19 |
| Ondansetron Odt | Ondansetron | 83 | 32 |
| Fluconazole | Fluconazole | 82 | 56 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 79 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 78 | 31 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 77 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 28 |
| Liothyronine Sodium | Liothyronine Sodium | 76 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 76 | 15 |
| Doxepin Hcl | Doxepin Hcl | 73 | 25 |
| Meloxicam | Meloxicam | 73 | 30 |
| Simvastatin | Simvastatin | 73 | 18 |
| Azelastine Hcl | Azelastine Hcl | 72 | 37 |
| Ropinirole Hcl | Ropinirole Hcl | 71 | 16 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 70 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 69 | 59 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 68 | 46 |
| Allopurinol | Allopurinol | 67 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 21 |
| Ezetimibe | Ezetimibe | 65 | 16 |
| Fenofibrate | Fenofibrate | 65 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | 21 |
| Testosterone Cypionate | Testosterone Cypionate | 64 | 14 |
| Nifedipine Er | Nifedipine | 63 | 24 |
| Mounjaro | Tirzepatide | 61 | 13 |
| Eszopiclone | Eszopiclone | 60 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 19 |
| Clonidine | Clonidine | 59 | 15 |
| Temazepam | Temazepam | 58 | suppressed |
| Januvia | Sitagliptin Phosphate | 57 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 17 |
| Linzess | Linaclotide | 55 | 18 |
| Lubiprostone | Lubiprostone | 53 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 52 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 18 |
| Colchicine | Colchicine | 49 | 16 |
| Ketoconazole | Ketoconazole | 48 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 19 |
| Topiramate | Topiramate | 48 | 16 |
| Warfarin Sodium | Warfarin Sodium | 48 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 46 | suppressed |
| Azithromycin | Azithromycin | 44 | 36 |
| Bumetanide | Bumetanide | 44 | 11 |
| Diazepam | Diazepam | 44 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | 13 |
| Lacosamide | Lacosamide | 43 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 42 | 17 |
| Rabeprazole Sodium | Rabeprazole Sodium | 41 | 13 |
| Risperidone | Risperidone | 41 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 41 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 13 |
| Myrbetriq | Mirabegron | 40 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | suppressed |
| Levofloxacin | Levofloxacin | 39 | 33 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 27 |
| Nystatin | Nystatin | 36 | 22 |
| Promethazine Hcl | Promethazine Hcl | 36 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 35 | suppressed |
| Rexulti | Brexpiprazole | 35 | suppressed |
| Ibuprofen | Ibuprofen | 34 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 33 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 33 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 33 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Lactulose | Lactulose | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 29 |
| Cilostazol | Cilostazol | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Torsemide | Torsemide | 31 | 14 |
| Gemtesa | Vibegron | 30 | suppressed |
| Ranolazine Er | Ranolazine | 30 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 18 |
| Terbinafine Hcl | Terbinafine Hcl | 29 | 15 |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 24 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 24 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Trulance | Plecanatide | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 19 |
| Levetiracetam Er | Levetiracetam | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Metolazone | Metolazone | 22 | 13 |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 15 |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Belsomra | Suvorexant | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Nadolol | Nadolol | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 11 |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Nystop | Nystatin | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 12 |
| Trulicity | Dulaglutide | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | 14 |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 13 | suppressed |
| Paliperidone Er | Paliperidone | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Alprazolam Er | Alprazolam | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Dupixent Pen | Dupilumab | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Eplerenone | Eplerenone | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Neupro | Rotigotine | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,263.64 · 69 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, Auvelity, Azstarys, BREZTRI, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, GARDASIL 9, GEMTESA, Kerendia, Korlym, MOUNJARO, NEXLETOL, NURTEC ODT, Ozempic, RELISTOR, REXULTI, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, VYNDAQEL, WAKIX, Wegovy, XIFAXAN, Xhance | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error